(S)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one manufacturers
- RBN-2397
-
- $97.00
-
2026-07-14
- CAS:2381037-82-5
- Purity: 99.90%
- Supply Ability: 10g
- RBN-2397
-
- $97.00
-
2026-07-14
- CAS:2381037-82-5
- Purity: 99.90%
- Supply Ability: 10g
|
| | (S)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one Basic information |
| Product Name: | (S)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one | | Synonyms: | (S)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one;Cpd 561;3(2H)-Pyridazinone, 5-[[(1S)-1-methyl-2-[3-oxo-3-[4-[5-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propoxy]ethyl]amino]-4-(trifluoromethyl)-;Atamparib (RBN-2397);4-[[(2S)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1H-pyridazin-6-one;RBM-2397;inhibit,carcinoma,Inhibitor,RBN-2397,NSCLC,RBN 2397,PARP,advanced,metastatic,squamous,cell,ovarian,poly ADP ribose polymerase,solid,RBN2397,tumor,lung;RNB-2397 | | CAS: | 2381037-82-5 | | MF: | C20H23F6N7O3 | | MW: | 523.43 | | EINECS: | | | Product Categories: | | | Mol File: | 2381037-82-5.mol |  |
| | (S)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one Chemical Properties |
| density | 1.53±0.1 g/cm3(Predicted) | | solubility | DMSO:200.0(Max Conc. mg/mL);382.1(Max Conc. mM) | | form | A crystalline solid | | pka | 9.56±0.60(Predicted) | | color | White to off-white | | InChIKey | UQZCQKXJAXKZQH-LBPRGKRZSA-N | | SMILES | C1(=O)NN=CC(N[C@@H](C)COCCC(=O)N2CCN(C3=NC=C(C(F)(F)F)C=N3)CC2)=C1C(F)(F)F |
| | (S)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one Usage And Synthesis |
| Uses | RBN-2397 can be prepared as a PARP7 inhibitor, which is useful for treating cancer. | | in vivo | RBN-2397 (oral administration; 3-100 mg/kg; once daily; 24-32 days) induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses in CT26 tumor-bearing BALB/c mice[2].RBN-2397 (oral administration; 3-100 mg/kg; once daily; 32 days) causes complete regressions at the dose 100 mg/kg and exerts a dose-dependent effects on tumor growth at dose levels of ≥30 mg/kg[2].The half-life (t1/2) of RBN-2397 in vivo is 325 mins[2]. | Animal Model: | CB17 SCID mice with NCI-H1373 xenografts[2] | | Dosage: | 3 mg/kg, 10mg/kg, 30 mg/kg, 100 mg/kg | | Administration: | Oral administration; once daily; 24-32 days | | Result: | Decreased tumor volume and exerted anti-tumor effects. |
| | IC 50 | PARP-7: 3 nM (IC50); PARP-7: 1 nM (Kd) |
| | (S)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one Preparation Products And Raw materials |
|